Clinical Trials · NCT00094146
Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Novartis
- Enrollment
- 160
- Start date
- Jan 2002
- Locations
- 3 sites, United States
- Primary endpoint
- The percent change at baseline compared to 6 months in body weight